Literature DB >> 20555071

Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M Baccarani1, M Dreyling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20555071     DOI： 10.1093/annonc/mdq201

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  16 in total

Review 1.  Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.

Authors:  Lucien Noens; Marja Hensen; Izabela Kucmin-Bemelmans; Christina Lofgren; Isabelle Gilloteau; Bernard Vrijens
Journal:  Haematologica       Date:  2014-03       Impact factor: 9.941

Review 2.  Management of advanced-phase chronic myeloid leukemia.

Authors:  Zachariah DeFilipp; Hanna Jean Khoury
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

3.  Second-generation TKIs: which and when?

Authors:  G Saglio
Journal:  Leuk Suppl       Date:  2012-08-09

4.  Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.

Authors:  Martin A Champagne; Cecilia H Fu; Myron Chang; Helen Chen; Robert B Gerbing; Todd A Alonzo; Linda D Cooley; Nyla A Heerema; Vivian Oehler; Charlotte Wood; Mary Ellen French; Robert J Arceci; Franklin O Smith; Mark L Bernstein
Journal:  Pediatr Blood Cancer       Date:  2011-04-04       Impact factor: 3.167

5.  Spontaneous Soft Tissue Haematomas- A Rare Presentation of Chronic Myeloid Leukemic (CML).

Authors:  Manoj Lakhotia; Hans Raj Pahadiya; Gopal Raj Prajapati; Akanksha Choudhary; Ronak Gandhi
Journal:  J Clin Diagn Res       Date:  2015-07-01

6.  Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study.

Authors:  Peter C Trask; Debanjali Mitra; Shrividya Iyer; Sean D Candrilli; James A Kaye
Journal:  Int J Hematol       Date:  2012-03-30       Impact factor: 2.490

7.  cDNA synthesis for BCR-ABL1 detection at the MMR level: the importance of using the appropriate kit.

Authors:  Jianxiang Chi; Chryso Pierides; Andrie Mitsidou; Andri Miltiadou; Petroula Gerasimou; Paul Costeas
Journal:  Biol Proced Online       Date:  2015-02-09       Impact factor: 3.244

8.  Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy.

Authors:  Leiming Xia; Wei Qian; Mingzhen Yang; Qingsheng Li; Fei Liu; Yanyan Xie
Journal:  Onco Targets Ther       Date:  2015-09-07       Impact factor: 4.147

9.  Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil.

Authors:  Monica Napoleão Fortes Rego; Konradin Metze; Irene Lorand-Metze
Journal:  Clinics (Sao Paulo)       Date:  2015-05-01       Impact factor: 2.365

Review 10.  Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia.

Authors:  Stephanie Bauer; Edie Romvari
Journal:  J Adv Pract Oncol       Date:  2012-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.